Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis

Ebara, Masaaki; Ohto, Masao; Shinagawa, Takashi; Sugiura, Norío; Kimura, Kazuhiro; Matsutani, Shoichi; Murakami, Masahiko; Saisho, Hiromitsu; Tsuchiya, Yukihiro; Okuda, Kunio

doi:10.1016/0016-5085(86)90923-6

Cited by 393 publications

(183 citation statements)

References 20 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Previous study found that approximately one third of small HCC (less than 3 cm) may secrete little or no AFP into the circulation (Ebara et al, 1986). Our data imply that the limitation of low specificity of AFP in diagnosing small HCC might be compensated by microsatellite analysis on cell-free DNA in cancer patients.…”

Section: Genetics and Genomicsmentioning

confidence: 55%

“…Measurement of serum AFP and hepatic ultrasonography are widely used as surveillance modalities for patients with high-risk of liver cancer. In patients with HCC, however, around one-third of small tumour (53 cm) was shown to secrete little or no AFP into the circulatory system (Ebara et al, 1986). As a result, it is mandatory to explore supplementary tumour marker for early detection of HCC.…”

Section: Discussionmentioning

confidence: 99%

“…Measurement of serum a-fetoprotein (AFP) and hepatic ultrasonography are widely used as surveillance modalities for high-risk patients. Elevated levels of AFP, with normal range set at 20 ng ml 71 , are detected in up to 75% of HCC patients, and values above 400 ng ml 71 are considered diagnostic for HCC (Ebara et al, 1986). However, 35% of HCC smaller than 3 cm may secrete little or no AFP into the circulation and thus will not be identified by this test (Ebara et al, 1986).…”

mentioning

confidence: 99%

“…Elevated levels of AFP, with normal range set at 20 ng ml 71 , are detected in up to 75% of HCC patients, and values above 400 ng ml 71 are considered diagnostic for HCC (Ebara et al, 1986). However, 35% of HCC smaller than 3 cm may secrete little or no AFP into the circulation and thus will not be identified by this test (Ebara et al, 1986). As a result, measurement of AFP alone is not an ideal test for early diagnosis of HCC.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum

Chang¹,

Ho²,

Chen³

et al. 2002

Br J Cancer

View full text Add to dashboard Cite

Frequent loss of heterozygosity of microsatellites markers on specific chromosomal region have been reported in various types of primary human cancer. The same loss of heterozygosity has also been identified in the matched plasma/serum DNA. Using 109 microsatellite markers representing 24 chromosomal arms, we have examined the loss of heterozygosity in 21 cases of hepatocellular carcinoma, six of cholangiocarcinoma, and 27 cases of chronic hepatitis or cirrhosis. All cases of the hepatocellular carcinoma showed deletion from two to 10 chromosomal arms, while deletion of chromosomes from two to eight regions was detected in five of six cholangiocarcinoma patients. One or more loss of heterozygosity in the paired serum DNA could be detected in 16 of 25 (76.2%) hepatocellular carcinoma patients. In contrast, no alterations in serum DNA test could be found in cholangiocarcinoma patients. Five of seven (71.4%) hepatocellular carcinoma patients with alpha-fetoprotein levels less than 20 ng ml 71 produced positive serum DNA test. The profiles of 19 microsatellite markers gave a 100% positive predictive value and an 80.8% negative predictive value for hepatocellular carcinoma. In conclusion, we have determined a profile of microsatellite markers appropriate for differential diagnosis of primary liver cancer. The discovery may permit a high-throughput screening of hepatocellular carcinoma at an early stage of disease.

show abstract

Section: Genetics and Genomicsmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum

Chang¹,

Ho²,

Chen³

et al. 2002

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…36 Elevated serum levels of alpha-fetoprotein, which reflect not only tumor-cell proliferation but also active disease with continuous necrosis and regeneration, are associated with an elevated risk of developing HCC. 37,38 Although the development of HCC is often followed by a steady increase in the alpha-fetoprotein levels, 37 the neoplastic changes are not necessarily associated with the elevated alpha-fetoprotein levels. In fact, many HCC lesions do not express alpha-fetoprotein even in the advanced stages.…”

Section: Discussionmentioning

confidence: 99%

Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma

Morimoto

Numata

Kondou

et al. 2010

Cancer

287

View full text Add to dashboard Cite

BACKGROUND:To improve the efficacy of radiofrequency ablation (RFA) for the treatment of intermediate-sized hepatocellular carcinomas (HCCs), the authors compared RFA combined with transcatheter arterial chemoembolization (TACE) to RFA alone. METHODS: The authors randomly assigned 37 patients with solitary HCCs (diameter, 3.1-5.0 cm in the greatest dimension) to 2 groups: the TACE-RFA group, in which the patients received TACE followed by RFA on the same day, and the RFA group, in which the patients received only RFA. RESULTS: Technical success was achieved after 1.4 AE 0.5 RFA sessions in the RFA group and after 1.1 AE 0.2 RFA sessions in the TACE-RFA group (P < .01). The mean diameters of the longer and shorter axes of the RFA-induced ablated areas were 50 AE 8.0 mm and 41 AE 7.1 mm, respectively, in the RFA group and 58 AE 13.2 mm and 50 AE 11.3 mm, respectively, in the TACE-RFA group; the mean diameters of the shorter axes were significantly different (P ¼ .012). The rates of local tumor progression at the end of the third year in the RFA and TACE-RFA groups were 39% and 6%, respectively (P ¼ .012). The 3-year survival rates of the patients in the RFA and TACE-RFA groups were 80% and 93%, respectively (P ¼ .369). CONCLUSIONS: In patients with intermediate-sized HCCs, RFA combined with TACE is more effective than RFA alone for extending the ablated area in fewer treatment sessions and for decreasing the local tumor progression rate. Cancer 2010;116:5452-60.

show abstract